Biotech VCs have become like bankers and we might all pay the price

In recent years, venture capitalists in the biotech sector have adopted strategies more akin to traditional bankers, focusing on quick returns and short-term gains. This shift clashes with the lengthy and costly process of drug development, which typically spans years and requires sustained investment. The potential consequence is that innovative but slower-moving projects may be sidelined, impacting the future of medical advancements and possibly leading to higher costs for consumers if breakthroughs are delayed. This trend underscores a critical tension between financial markets' immediate demands and the long-term needs of scientific progress.